Cancer vaccines: advances, hurdles, and future directions

Area of Science:

• Immunology
• Oncology
• Vaccinology

Background:

• Therapeutic cancer vaccines leverage the adaptive immune system to eliminate tumors by targeting tumor-specific antigens.
• The field has evolved from shared tumor-associated antigens (TAAs) and dendritic cell (DC) vaccines to advanced neoantigen-based messenger ribonucleic acid (mRNA) vaccines.

Purpose of the Study:

• To review the evolution of cancer vaccine platforms, from early approaches to next-generation mRNA vaccines.
• To highlight advancements in vaccine delivery, antigen discovery, computational prediction, and translational efficacy.
• To discuss challenges and propose an integrated ecosystem for personalized cancer vaccine adoption.

Main Methods:

• Review of historical and current cancer vaccine platforms.
• Analysis of clinical data for neoantigen mRNA vaccines.
• Exploration of challenges in tumor heterogeneity, manufacturing, biomarkers, and regulatory frameworks.

Main Results:

• Significant progress in vaccine delivery, antigen discovery, and computational prediction.
• Demonstration of long-lived T-cell memory and promising clinical outcomes in pancreatic ductal adenocarcinoma (PDAC), melanoma, head and neck cancers, and renal cell carcinoma (RCC).
• Identification of key challenges hindering widespread adoption.

Conclusions:

• Next-generation neoantigen mRNA vaccines represent a significant advancement in cancer immunotherapy.
• Overcoming challenges in heterogeneity, manufacturing, biomarkers, and regulation is crucial for accelerating personalized cancer vaccine development.
• An integrated translational ecosystem is proposed to facilitate the adoption of these innovative therapies.